A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer (ROCKET)
Sponsor: EpicentRx, Inc.
Listed as NCT02096354, this PHASE2 trial focuses on Colorectal Neoplasms and remains completed. Sponsored by EpicentRx, Inc., it has been updated 12 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Nov 2024 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2021 — Jun 2022 [monthly]
Active Not Recruiting PHASE2
▶ Show 7 earlier versions
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Dec 2019 — Aug 2020 [monthly]
Active Not Recruiting PHASE2
-
Jul 2018 — Dec 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Aug 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
May 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- EpicentRx, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .